Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, Beigene, CSPC Zhongqi Pharmaceutical Technology, Lintonpharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceuticals

(MENAFN- GetNews)

DelveInsight's,
“Advanced Gastric Carcinoma Pipeline Insight, 2024,”
report provides comprehensive insights about
50+ companies and 50+ pipeline drugs
in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Gastric Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Gastric Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report

• July 2024:- AstraZeneca- A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03).
• July 2024:- LaNova Medicines Zhejiang Co., Ltd.- A Phase III, Open-Label, Multi Center, Randomized Study of LM-302 Versus Treatment of Physician's Choice (TPC) in Patients With CLDN18.2-Positive, Locally Advanced or Metastatic Gastric(GC) and Gastroesophageal Junction(GEJ) Adenocarcinoma.
• DelveInsight's Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
• The leading Advanced Gastric Carcinoma Companies such as Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
• Promising Advanced Gastric Carcinoma Therapies such as MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.

Stay informed about the cutting-edge advancements in Advanced Gastric Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Gastric Carcinoma Clinical Trials Assessment

Advanced Gastric Carcinoma Emerging Drugs Profile

• Camrelizumab: Jiangsu Hengrui Medicine

Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.

• Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Learn more about Advanced Gastric Carcinoma Drugs Opportunities in our groundbreaking Advanced Gastric Carcinoma Research and development projects @ Advanced Gastric Carcinoma Unmet Needs

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Advanced Gastric Carcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Discover the latest advancements in Advanced Gastric Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Gastric Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Gastric Carcinoma Pipeline Report

• Coverage- Global
• Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
• Advanced Gastric Carcinoma Therapies- MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.
• Advanced Gastric Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Gastric Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Gastric Carcinoma Pipeline on our website @ Advanced Gastric Carcinoma Emerging Drugs and Companies

Table of Content